- Poster presentation
- Open Access
Prophylactic treatment with bicillin-5 and timalin of convalescence of erysipelas
© Iarovoi et al; licensee BioMed Central Ltd. 2013
- Published: 16 December 2013
- Public Health
- High Risk
- Internal Medicine
- Infectious Disease
- Antibiotic Resistance
Administration of bicillin-5 alone in contemporary conditions of increasing antibiotic resistance and immunodeficiency of population is insufficient to prevent the recurrences of erysipelas. That is why a decision was made to study timalin as an immunomodulatory drug that would prevent along with bicillin-5 the recurrence of erysipelas.
52 patients with a recent history of erysipelas and with a high risk of relapse were divided into 2 groups of 26 patients each: one the experimental group in which patients received both bicillin-5 (IM, monthly for 6 or 12 months) and timalin (10 mg IM in a day, in 10 doses) and one control group, in which only bicillin-5 was prescribed. Patients from both groups were supervised epidemiologically, clinically and immunologically for 1-4 years.
The relapse rate in the experimental group was 2 times lower (19.2%) than in the control group (38.5%). Recurrences of erysipelas in the experimental group occurred during bicillin-5 prophylactic treatment in 2 cases: in the third and sixth month. Out of the 10 patients with relapses in the control group, in 3 the relapses occurred before completing prophylactic treatment with bicillin-5.
Due to its immunocorrector effects, Timalin lowers the risk of relapses in erysipelas.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.